PMID- 20002520
OWN - NLM
STAT- MEDLINE
DCOM- 20100308
LR  - 20151119
IS  - 1471-4159 (Electronic)
IS  - 0022-3042 (Linking)
VI  - 112
IP  - 4
DP  - 2010 Feb
TI  - Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and 
      vesicular monoamine transporter 2 protein and gene expression in rats: 
      implications for MDMA neurotoxicity.
PG  - 951-62
LID - 10.1111/j.1471-4159.2009.06515.x [doi]
AB  - 3,4-Methylenedioxymethamphetamine (MDMA; 'Ecstasy') is a popular recreational 
      drug used worldwide. This study aimed to determine the effects of this compound 
      on the expression of nerve terminal serotonergic markers in rats. Experiment 1 
      investigated MDMA-induced changes in levels of the serotonin transporter (SERT) 
      and the vesicular monoamine transporter 2 (VMAT-2) in the hippocampus, a region 
      with sparse dopaminergic innervation, after lesioning noradrenergic input with 
      N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4). Adult male Sprague-Dawley 
      rats were administered 100 mg/kg DSP-4 or saline 1 week prior to either an MDMA 
      (10 mg/kg x 4) or saline binge. Two weeks following the binge treatment, the 
      DSP-4/MDMA group unexpectedly showed little change in hippocampal VMAT-2 protein 
      expression compared with DSP-4/Saline controls, despite large reductions in SERT 
      levels in all regions examined in the MDMA-treated animals. Furthermore, animals 
      treated with binge MDMA (Experiment 2) showed a striking decrease in SERT gene 
      expression (and a lesser effect on VMAT-2) measured by quantitative RT-PCR in 
      pooled dorsal and median raphe tissue punches, when compared with saline-treated 
      controls. These results demonstrate that MDMA causes substantial regulatory 
      changes in the expression of serotonergic markers, thus questioning the need to 
      invoke distal axotomy as an explanation of MDMA-related serotonergic deficits.
FAU - Biezonski, Dominik K
AU  - Biezonski DK
AD  - Neuroscience and Behavior Program, University of Massachusetts, Amherst, 
      Massachusetts, USA.
FAU - Meyer, Jerrold S
AU  - Meyer JS
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20091130
PL  - England
TA  - J Neurochem
JT  - Journal of neurochemistry
JID - 2985190R
RN  - 0 (Benzylamines)
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Hallucinogens)
RN  - 0 (Neurotransmitter Uptake Inhibitors)
RN  - 0 (Serotonin Plasma Membrane Transport Proteins)
RN  - 0 (Slc18a2 protein, rat)
RN  - 0 (Vesicular Monoamine Transport Proteins)
RN  - 31363-74-3 (5,7-Dihydroxytryptamine)
RN  - 333DO1RDJY (Serotonin)
RN  - 44RAL3456C (Methamphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - PQ1P7JP5C1 (DSP 4)
SB  - IM
MH  - 5,7-Dihydroxytryptamine/pharmacology
MH  - Animals
MH  - Area Under Curve
MH  - Benzylamines/pharmacology
MH  - Brain/drug effects/metabolism/pathology
MH  - Central Nervous System Stimulants/administration & dosage
MH  - Disease Models, Animal
MH  - Female
MH  - Gene Expression/drug effects
MH  - Hallucinogens/*toxicity
MH  - Male
MH  - Methamphetamine/administration & dosage
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*toxicity
MH  - Neurotoxicity Syndromes/*etiology/pathology/prevention & control
MH  - Neurotransmitter Uptake Inhibitors/pharmacology
MH  - Pregnancy
MH  - Protein Binding/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonin/metabolism
MH  - Serotonin Plasma Membrane Transport Proteins/*metabolism
MH  - Synaptosomes/drug effects/metabolism
MH  - Time Factors
MH  - Vesicular Monoamine Transport Proteins/*metabolism
EDAT- 2009/12/17 06:00
MHDA- 2010/03/10 06:00
CRDT- 2009/12/17 06:00
PHST- 2009/12/17 06:00 [entrez]
PHST- 2009/12/17 06:00 [pubmed]
PHST- 2010/03/10 06:00 [medline]
AID - JNC6515 [pii]
AID - 10.1111/j.1471-4159.2009.06515.x [doi]
PST - ppublish
SO  - J Neurochem. 2010 Feb;112(4):951-62. doi: 10.1111/j.1471-4159.2009.06515.x. Epub 
      2009 Nov 30.